- Home
- VRTX
VRTX
Vertex Pharmaceuticals Incorporated
as 04-25-2025 10:44am EST
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 1991 |
| Target Price: | $512.30 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $377.85 - $519.88 | Next Earning Date: | 05-05-2025 |
| Revenue: | $11,020,100,000 | Revenue Growth: | 11.66% |
| Revenue Growth (this year): | 10.71% | Revenue Growth (next year): | 9.46% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 13 '25 | Sell | $510.00 | 3,231 | $1,647,810.00 | 23,281 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Mar 10 '25 | Sell | $499.99 | 3,242 | $1,620,967.58 | 51,239 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 10 '25 | Sell | $500.00 | 3,231 | $1,615,500.00 | 23,281 | |
| WAGNER CHARLES F JR | VRTX | EVP & Chief Financial Officer | Mar 10 '25 | Sell | $500.00 | 3,298 | $1,649,000.00 | 51,671 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Mar 4 '25 | Sell | $485.49 | 4,058 | $1,970,118.42 | 51,239 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 3 '25 | Sell | $490.00 | 3,231 | $1,583,190.00 | 23,281 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 26 '25 | Sell | $475.34 | 530 | $251,930.20 | 51,239 | |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 26 '25 | Sell | $475.34 | 2,650 | $1,259,651.00 | 19,352 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Feb 26 '25 | Sell | $480.00 | 1,272 | $610,560.00 | 23,281 | |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 24 '25 | Sell | $480.95 | 884 | $425,159.80 | 9,086 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Zacks
18 hours ago
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts
Pharmaceutical Technology
a day ago
Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds
Zacks
2 days ago
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Motley Fool
3 days ago
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Motley Fool
3 days ago
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Zacks
3 days ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Motley Fool
3 days ago
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right
Simply Wall St.
4 days ago
Vertex Pharmaceuticals (NasdaqGS:VRTX) Faces UK Patent Lawsuit Over Groundbreaking CASGEVY Therapy
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.